Karius IPO

Karius has developed a liquid biopsy test that can identify more than 1,000 pathogens from a single blood draw using next-generation sequencing and machine learning. The Karius Test analyzes microbial cell-free DNA in plasma to detect bacteria, fungi, viruses, and parasites, providing results in about 24 hours compared to traditional culture methods that can take days or weeks. This technology is particularly valuable for immunocompromised patients, those with suspected bloodstream infections, and cases where traditional diagnostic methods have failed to identify the causative pathogen. The company's approach addresses a critical gap in infectious disease diagnostics, where rapid pathogen identification can significantly impact patient outcomes and antibiotic stewardship. Karius has gained adoption in major hospital systems and has been particularly relevant during the COVID-19 pandemic for detecting co-infections and understanding complex infectious disease presentations.